Audited Financial Results of the Company for the half yeaar and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals reported total income of Rs. 31,070 Lakhs for FY26, up from Rs. 30,733 Lakhs in FY25, a modest ~1% increase. Revenue from operations grew to Rs. 28,279 Lakhs from Rs. 26,374 Lakhs (~7.2% growth). Net profit increased significantly to Rs. 1,015 Lakhs from Rs. 790 Lakhs, representing ~28.5% year-on-year growth. The statutory auditors issued an unmodified (clean) audit opinion, and no key audit matters were flagged. The company raised Rs. 112.83 Lakhs via warrant conversion during the period. Cash and cash equivalents declined sharply from Rs. 30.24 Lakhs to Rs. 5.82 Lakhs during the year.
The clean audit opinion and strong PAT growth of ~28.5% are positive signals for shareholders, though the modest revenue growth and sharp decline in cash balances warrant monitoring.